{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:02:34Z","timestamp":1790794954398,"version":"4.1.0"},"reference-count":98,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Treatment of relapsed\/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment-related factors should be considered at all stages of the disease. RRMM is based on definitions of the international myeloma working group (IMWG) and includes biochemical progression, such as paraprotein increase, or symptomatic relapse with CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions). When choosing RRMM-treatment, the biochemical markers for progression and severity of the disease, dynamic of disease relapse, type and number of prior therapy lines, including toxicity and underlying health status, need to be considered, and shared decision making should be pursued. Objectively characterizing health status via geriatric assessment (GA) at each multiple myeloma (MM) treatment decision point has been shown to be a better estimate than via age and comorbidities alone. The well-established national comprehensive cancer network, IMWG, European myeloma network and other national treatment algorithms consider these issues. Ideally, GA-based clinical trials should be supported in the future to choose wisely and efficaciously from available intervention and treatment options in often-older MM adults in order to further improve morbidity and mortality.<\/jats:p>","DOI":"10.3390\/cancers13174320","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T09:53:23Z","timestamp":1630058003000},"page":"4320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Choosing the Right Therapy for Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors"],"prefix":"10.3390","volume":"13","author":[{"given":"Laura","family":"Gengenbach","sequence":"first","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Graziani","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"R\u00f6sner","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Braun","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy-Deborah","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Greil","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Knop","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1080\/10428194.2018.1448084","article-title":"Navigating the changing multiple myeloma treatment landscape: Clinical practice patterns of MM patients treated in- and outside German DSMM study group trials","volume":"59","author":"Gengenbach","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_6","first-page":"e51","article-title":"Multidisciplinary Tumor Boards: Facts and Satisfaction Analysis of an Indispensable Comprehensive Cancer Center Instrument","volume":"142","author":"Engelhardt","year":"2017","journal-title":"DMW Dtsch. Med. Wochenschr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","article-title":"Management of multiple myeloma in older adults: Gaining ground with geriatric assessment","volume":"8","author":"Wildes","year":"2016","journal-title":"J. Geriatr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/cncr.32978","article-title":"Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients","volume":"126","author":"Schinke","year":"2020","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1200\/JCO.21.00242","article-title":"Advances in Management for Older Adults With Hematologic Malignancies","volume":"39","author":"Rosko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"LaRocca","year":"2018","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: Validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.clml.2019.04.014","article-title":"Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis","volume":"19","author":"Salazar","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2011","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2015","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-015-2405-0","article-title":"Trained clinical nurse specialists proficiently obtain bone marrow aspirates and trephine biopsies in a nearly painless procedure\u2014A prospective evaluation study","volume":"94","author":"Naegele","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.3324\/haematol.2019.238394","article-title":"Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma","volume":"105","author":"Dold","year":"2020","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","article-title":"European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when","volume":"103","author":"Caers","year":"2018","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: Definition, disease assessment and treatment considerations","volume":"194","author":"Beksac","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhou, X., Dierks, A., Kertels, O., Samnick, S., Kircher, M., Buck, A.K., Haertle, L., Knorz, S., B\u00f6ckle, D., and Scheller, L. (2020). The Link between Cytogenetics\/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed\/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET\/CT. Cancers, 12.","DOI":"10.3390\/cancers12092399"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.5045\/br.2020.S008","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00277-018-3361-2","article-title":"Real-world data on Len\/Dex combination at second-line therapy of multiple myeloma: Treatment at biochemical relapse is a significant prognostic factor for progression-free survival","volume":"97","author":"Katodritou","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: Time for a new definition?","volume":"122","author":"Dispenzieri","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3324\/haematol.2020.262758","article-title":"Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical Features Associated with COVID-19 Outcome in multiple meloma: First results from International Myeloma Society COVID-19 Dataset","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: A consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.1002\/cam4.3460","article-title":"Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany","volume":"9","author":"Shoumariyeh","year":"2020","journal-title":"Cancer Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jgo.2020.04.008","article-title":"Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma","volume":"11","author":"Mian","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1177\/1352458520943783","article-title":"COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment","volume":"26","author":"Dersch","year":"2020","journal-title":"Mult. Scler. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3324\/haematol.2016.154807","article-title":"Autotransplants in older multiple myeloma patients: Hype or hope in the era of novel agents?","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2020.254235","article-title":"Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial","volume":"106","author":"Dold","year":"2020","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Engelhardt, M., Ihorst, G., Schumacher, M., Rassner, M., Gengenbach, L., M\u00f6ller, M., Shoumariyeh, K., Neubauer, J., Farthmann, J., and Herget, G. (2021). Multidisciplinary tumor boards and their analyses: The yin and yang of outcome measures. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07878-6"},{"key":"ref_46","first-page":"E59","article-title":"Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis","volume":"23","author":"Duffner","year":"2019","journal-title":"Hemodial. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2018","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jgo.2020.11.003","article-title":"Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation","volume":"12","author":"Ihorst","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany","volume":"21","author":"Engelhardt","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1002\/cncr.33658","article-title":"Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort","volume":"127","author":"Scheubeck","year":"2021","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/gerona\/glw067","article-title":"Declines and Impairment in Executive Function Predict Onset of Physical Frailty","volume":"71","author":"Gross","year":"2016","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejh.13530","article-title":"Survival trends in elderly myeloma patients","volume":"106","author":"Jones","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.12837","article-title":"Age disparities in survival from lymphoma and myeloma: A comparison between US and England","volume":"165","author":"Pulte","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in Older Adults: Evidence for a Phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1158\/1078-0432.CCR-14-2154","article-title":"Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time","volume":"21","author":"Hieke","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: Comparative evaluation of common comorbidity scores and use of a novel MM\u2013comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","article-title":"Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome","volume":"13","author":"Kleber","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00043","article-title":"Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma","volume":"2","author":"Mian","year":"2018","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.19.02809","article-title":"Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review","volume":"38","author":"Dumontier","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: Towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bobin, A., Liuu, E., Moya, N., Gruchet, C., Sabirou, F., L\u00e9vy, A., Gardeney, H., Nsiala, L., Cailly, L., and Guidez, S. (2020). Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. Cancers, 12.","DOI":"10.3390\/cancers12102885"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood.V126.23.394.394","article-title":"A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial","volume":"126","author":"Cook","year":"2015","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","article-title":"High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Rasche, L., W\u00e4sch, R., Munder, M., Goldschmidt, H., and Raab, M.S. (2021). Novel immunotherapies in multiple myeloma\u2014Chances and challenges. Haematologica.","DOI":"10.3324\/haematol.2020.266858"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mateos, M.-V., Blad\u00e9, J., Bringhen, S., Ocio, E.M., Efebera, Y., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., and Richardson, P.G. (2020). Melflufen: A Peptide\u2013Drug Conjugate for the Treatment of Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103120"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"ref_81","first-page":"166","article-title":"Antibody Treatment in Multiple Myeloma","volume":"19","author":"Maples","year":"2021","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zhou, X., Einsele, H., and Danhof, S. (2020). Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072166"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Caraccio, C., Krishna, S., Phillips, D., and Sch\u00fcrch, C.M. (2020). Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00501"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3324\/haematol.2019.228676","article-title":"Teaming up for CAR-T cell therapy","volume":"104","author":"Munder","year":"2019","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2019","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy Combinations in Multiple Myeloma\u2014Known Unknowns","volume":"379","author":"Gormley","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/cncr.31243","article-title":"Current developments in immunotherapy in the treatment of multiple myeloma","volume":"124","author":"Greil","year":"2018","journal-title":"Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3324\/haematol.2018.188516","article-title":"Osteoprotective medication in the era of novel agents: A European perspective on values, risks and future solutions","volume":"103","author":"Engelhardt","year":"2018","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/10428194.2020.1849681","article-title":"Interdisciplinary approach to multiple myeloma\u2014Time to diagnosis and warning signs","volume":"62","author":"Herget","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/10428194.2019.1695051","article-title":"Time from first symptom onset to the final diagnosis of multiple myeloma (MM)\u2014Possible risks and future solutions: Retrospective and prospective \u2018Deutsche Studiengruppe MM\u2019 (DSMM) and \u2018European Myeloma Network\u2019 (EMN) analysis","volume":"61","author":"Graziani","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.2019.245423","article-title":"Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: The necessity of interdisciplinary state-of-the-art treatment","volume":"105","author":"Herget","year":"2020","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1080\/10428194.2018.1429605","article-title":"Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors","volume":"59","author":"Leng","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_96","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejh.12900","article-title":"Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study","volume":"99","author":"Reiser","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: Systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk. Lymphoma"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:07Z","timestamp":1760165587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":98,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174320"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174320","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}